Nevertheless, these data suggest targeting Akt in tumor–associated myeloid cells might be a valid strategy to switch an anti–inflammatory to a pro–inflammatory tumor microenvironment to induce antitumor responses and improve patient survival. The gene discussed is AKT1; the disease is neoplasm.